![Page 1: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/1.jpg)
Neuromuscular Blocking Agents
& Reversal
Dr.Mushtaq AhmadConsultant Anesthetist
BVH,BWP
![Page 2: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/2.jpg)
![Page 3: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/3.jpg)
CONTENTS Introduction/history Neuromuscular
transmission Distinctions Between
Depolarizing & Nondepolarizing Blockade...mechanism of actions
Classification depolarizing & Nondepolarizing Muscle Relaxants
Reversal ...Cholinesterase Inhibitors & Other Pharmacologic Antagonists to Neuromuscular Blocking Agents
![Page 4: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/4.jpg)
HISTORY
![Page 5: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/5.jpg)
![Page 6: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/6.jpg)
![Page 7: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/7.jpg)
in 1942, when Griffith and Johnson in Montreal used Intocostrin, a biologically standardized mixture of the alkaloids of the
• Indian rubber plant Chondrodendron tomentosum,to facilitate relaxation during cyclopropane anaesthesia.
However, as noted by Beecher and Todd in 1954:
• “muscle relaxants given inappropriately may provide the surgeon with optimal operating conditions in . . . • a patient [who] is paralyzed but not anesthetized—a state that is wholly unacceptable for the patient.” • In other words, muscle relaxation does not ensure unconsciousness, amnesia, or analgesia
![Page 8: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/8.jpg)
Definition
NMBA are the drugs that act peripherally at NM-Junction and muscle fiber itself to block neuromuscular transmission.
• In order to facilitate muscle relaxation for surgery and • mechanical ventilation during surgery & in ICU.
![Page 9: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/9.jpg)
Neuromuscular Transmission
![Page 10: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/10.jpg)
Neuromuscular junction
Association between a motor neuron and a muscle cell
• Synaptic cleft...The cell membranes of the neuron and muscle fiber are separated by a narrow (20-nm) gap
• Within the most distal aspect of the motor neuron, vesicles containing the neurotransmitter acetylcholine (ACh) can be found.
![Page 11: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/11.jpg)
![Page 12: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/12.jpg)
![Page 13: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/13.jpg)
![Page 14: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/14.jpg)
The postjunctional motor membrane ... motor end-plate is
• highly specialized and invaginated, and the shoulders of these folds are rich in ACh receptors
acetylcholinesterase ......
• Th is enzyme (also called specific cholinesterase or true cholinesterase) is• embedded into the motor end-plate membrane immediately adjacent to the
ACh receptors.
![Page 15: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/15.jpg)
Structure of ACh receptors
structure of ACh receptors varies in diff erent tissues and at different times in development……
• Nicotinic & muscurinic
Location of ACh receptors
• Post junctional nicotinic ACh recepters...... located on the postjunctional motor membrane-.motor end-plate...• approximately 5 million of these receptors, but activation of only about 500,000 receptors is required for normal muscle contraction• Prejunctional ACh receptors .......are present and influence the release of ACh.
• The prejunctional and postjunctional receptors have different affinities for ACh.• Extrajunctional ACh receptors .......are located throughout the skeletal muscle in relatively low numbers owing to suppression of their synthesis by normal
neural activity.
![Page 16: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/16.jpg)
Postjunctional ACh receptors, embedded in the lipid layer of the postsynaptic muscle membrane.
![Page 17: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/17.jpg)
Prejunctional Ach receptors
Pre- junctional acetylcholine receptors are present on the shoulders of the axon terminal,
• Ready for release on arrival of another nerve im-pulse. The mechanism requires ca2+ ions.
Stimulation of the prejunctional receptors mobilizes (MOB) the vesicles of acetylcholine to move into the active zone,
![Page 18: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/18.jpg)
Maturation of the postsynaptic apparatus. At approximately 14 days after birth, the immature γ-subunit–containing acetylcholine receptors (AChRs) are completely replaced by mature AChRs containing α-subunit.The neuromuscular junction is completely developed at 30 days after birth
![Page 19: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/19.jpg)
Each ACh receptor in the neuromuscular junction normally consists of five protein subunits;
• two α subunits; and • single β, δ, and ε subunits.
Only the two identical α subunits are capable of binding ACh molecules.
• If both binding sites are occupied by ACh, a conformational change in the subunits briefl y (1 ms) opens an ion channel in the core of the receptor
![Page 20: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/20.jpg)
Ion channel in the core of the ach receptor
Only the two identical α subunits are capable of binding ACh molecules.
The channel will not open if ACh binds on only one site.
If both binding sites are occupied by ACh, a conformational change in the subunits briefl y (1 ms) opens an ion channel in the core of the receptor
![Page 21: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/21.jpg)
![Page 22: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/22.jpg)
Voltage-gated sodium channels
![Page 23: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/23.jpg)
sodium channel is a transmembrane protein that can be conceptualized as having two gates.
Sodium ions pass only when both gates are open.
Opening of the gates is time dependent and voltage dependent.
The channel therefore possesses three functional states.
A...At rest, the lower gate is open but the upper gate
is closed B...reaches threshold
voltage depolarization, the upper gate opens and
sodium can pass C...Shortly after the upper
gate opens the timedependent lower
gate closes
![Page 24: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/24.jpg)
![Page 25: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/25.jpg)
Fetal or immature extrajunctional ach recepters
• another isoform contains a γ subunit instead of the ε subunit. • Th is isoform initially expressed in fetal muscle. • It is also often referred to as extrajunctional because, unlike the mature
isoform, it may be located anywhere in the muscle membrane, inside or outside the neuromuscular junction when expressed in adults.
![Page 26: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/26.jpg)
Steps in normal NM transmission.
![Page 27: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/27.jpg)
![Page 28: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/28.jpg)
CLASSIFICATIONDISTINCTIONS
BETWEEN DEPOLARIZING & NON
DEPOLARIZING BLOCKADE
(Mechanism of Actions)
![Page 29: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/29.jpg)
Basis of Classification
Mechanism of action
Response to peripheral nerve
stimulation
Reversal of block.Duration of action
Chemistry
![Page 30: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/30.jpg)
![Page 31: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/31.jpg)
Classification-mechanism & duration of action
Depolarizing
Short-acting
• Succinylcholine
Nondepolarizing
Short-acting
• Gantacurium• Mivacurium • Rocuronium
Intermediate-acting
• Atracurium • Cisatracurium • Vecuronium • Rocuronium
Long-acting
• Pancuronium• Pipecuronium• Doxacurium
![Page 32: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/32.jpg)
Classification- Chemistry
Benzylisoquinolinium
Atracurium• tubocurarine• metocurine• gallamine,• alcuronium, , • decamethonium
Cisatracurium
Mivacurium
Doxacurium
AV002 (CW002)
Historical interest
Steroidal
Pancuronium
Vecuronium
Rocuronium
Pipecuronium
rapacuronium...historical interest
Others-chlorofumarates
Gantacurium
![Page 33: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/33.jpg)
MECHANISM OF ACTION of depolarizing NMBA
1 •Depolarizing muscle relaxants closely resemble ACh and readily bind to ACh receptors, generating a muscle action potential.
2 •Unlike ACh, however, these drugs are not metabolized by acetylcholinesterase, and their concentration in the synaptic cleft does not fall as rapidly, resulting in a prolonged depolarization of the muscle end-plate.
3 •Continuous end-plate depolarization causes muscle relaxation
4 •because opening of perijunctional sodium channels is time limited (sodium channels rapidly “inactivate” with continuing depolarization)
![Page 34: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/34.jpg)
Phases of block in Depolarizing NMBA
Phase-1 block
• Perijunctional VGSC cannot reopen until the end-plate repolarizes.• Th e end-plate cannot repolarize as long as the depolarizing muscle relaxant continues to
bind to ACh receptors; this is called a phase I block.
Phase ii Block
• Aft er a period of time, prolonged end-plate depolarization can cause poorly understood changes in the ACh receptor that result in a phase II block,
![Page 35: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/35.jpg)
Characteristics of Depolarizing Neuromuscular Block
In the presence of a small dose of succinylcholine:
• low-voltage (1 Hz) twitch stimulus applied to a peripheral nerve is detected.
1.a decreased response to a single
• no decrease in the height of successive stimuli is noted
2.Tetanic stimulation (e.g. at 50 Hz) produces a small, but sustained, response
• produces no potentiation of the twitch height; there is no post-tetanic potentiation (sometimes termed facilitation)
3.if four twitch stimuli are applied at 2 Hz over 2 s (train-of-four stimulus), followed by a 10-s inter-val before the next train-of-four
4.the application of a 5-s burst of tetanic stimula-tion after the application of single twitch stim-uli,…. followed 3 s later by a further run of twitch stimuli
![Page 36: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/36.jpg)
neuromuscular block is potentiated by the ad- ministration of an anticholinesterase such as neostigmine or edrophonium. OR if repeated doses of succinylcholine are given, the characteristics of this depolarizing block alter;
• signs typical of a non-depolarizing block develop • Initially, such changes are demonstrable only at fast rates of stimulation, • but with further increments of succinylcholine they may occur at slower rates.
This phenomenon is termed ‘dual block’.
muscle fasciculation is typical of a depolarizing block.
![Page 37: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/37.jpg)
![Page 38: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/38.jpg)
Mechanism of action of non-depolarizing NMBA
depolarizing muscle relaxants act as ACh receptor agonists,
whereas nondepolarizing muscle relaxants function as competitive antagonists.
Nondepolarizing muscle relaxants bind ACh receptors but are incapable of inducing the conformational change necessary for ion channel
opening.
Because ACh is prevented from binding to
its receptors, no end-plate potential develops.
Neuromuscular blockade occurs
even if only one α subunit is blocked.
![Page 39: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/39.jpg)
![Page 40: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/40.jpg)
Characteristics of Non-Depolarizing Neuromuscular Block
If a small, subparalysing dose of a non-depolarizing neuromuscular blocking drug is administered, the following characteristics are recognized:
• if repeated, decreases further in amplitude. This effect, which is in con-trast to that produced by a depolarizing drug,
1. decreased response to a low-voltage twitch stimulus (e.g. 1 Hz) which,
2.also occurs to a greater degree when the train-of-four (TOF) twitch response is applied, and even more so with higher, tetanic rates of stimulation. It is referred to as ‘fade’ or decrement.
![Page 41: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/41.jpg)
3. post-tetanic potentiation (PTP) or facilitation (PTF) of twitch response may be demonstrated
4.neuromuscular block is reversed by administration of ananticholinesterase.
5 no muscle fasciculation is visible.
![Page 42: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/42.jpg)
![Page 43: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/43.jpg)
![Page 44: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/44.jpg)
OTHER MECHANISMS OF NEUROMUSCULAR
BLOCKADE Interference with the function of the Ach receptor without acting as an agonist or antagonist.
Interfere with normal functioning of the Ach receptor binding site or with the opening and closing of the receptor channel.
• Example....• Inhaled anesthetic agents• local anesthetics• ketamine.
![Page 45: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/45.jpg)
closed or open channel blockade
• During closed channel blockade • the drug physically plugs up the channel, preventing passage of cations • whether or not ACh has activated the receptor.
• Open channel blockade• use dependent, • because the drug enters and obstructs the ACh receptor channel only aft er it is opened by ACh binding
• Example...channel block in the laboratory include• neostigmine, • some antibiotics, • cocaine, and • quinidine.
Other drugs may impair the presynaptic release of ACh
![Page 46: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/46.jpg)
MONITORING NEUROMUSCULAR BLOCKADE
Indications for Neuromuscular Monitoring….. preferable always to monitor neuromuscular function when a muscle relaxant is used during an-aesthesia
• 1.during prolonged anaesthesia, when repeated increments of neuromuscular blocking agents are required
• 2.when infusions of muscle relaxants are given ( including in the ICU)
![Page 47: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/47.jpg)
3.in the presence of renal or hepatic dysfunction
4. in patients with neuromuscular disorders
5.in patients with a history of sensitivity to a muscle relaxant or poor recovery from block
6.when poor reversal of neuromuscular block is encountered unexpectedly
![Page 48: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/48.jpg)
AAccelometer
![Page 49: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/49.jpg)
Nerve Stimulator CharacteristicsResponse of the nerve to electrical stimulation depends on three factors:
• The current applied• The duration of the current• The position of the electrodes
Black electrode of the stimulator is negatively charged, and the red electrode is positively charged
• The ulnar• Facial • Common peroneal nerve
Usually, a nerve which is readily accessible to the anaesthetist
• Visual or tactile means, or it may be • more sophisticated methods.
• Mechanomyography• Electromyography• Accelerography
The muscle response assessed by either
![Page 50: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/50.jpg)
Modes of StimulationSingle stimulus
TOF stimulation
Tetanic stimulation
Posttetanic facilitation and posttetanic count
Double-burst (DB) stimulation
![Page 51: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/51.jpg)
![Page 52: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/52.jpg)
Single twitch
stimulus of short duration (0.1–0.2 ms)
• if applied re-peatedly, before and after a dose of a muscle relaxant, it may be possible to assess the effects of the drug.
delivery of single impulses separated by at least 10 seconds.
It is of limited clinical use
![Page 53: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/53.jpg)
Train-of-Four (TOF) Twitch Response
Four stimuli (at 2 Hz) are applied over 2 s, with at least a 10-s gap between each TOF
• fade of the am -plitude of the TOF may be visible.
small dose of a non-depolarizing muscle relaxant
The ratio of the amplitude of the fourth to the first twitch is called the train-of-four ratio (TOFR).
![Page 54: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/54.jpg)
larger dose of such a drug,
• the fourth twitch disappears first, then the third, followed by the second and, finally, the first twitch• On recovery from neuro -muscular block, the first twitch appears first, then the second then the
third, and finally the fourth
at least three of the four twitches must be absent ……for upper abdominal surgery.
Full reversal can only be relied upon if at least the ……second twitch is visible when an anticholinesterase is given.
![Page 55: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/55.jpg)
![Page 56: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/56.jpg)
After reversal
• good muscle tone – as assessed clinically ….being able to cough, raise his or her head from the pillow for at least 5 s, protrude the tongue and have good grip strength – may be anticipated when the TOFR has reached at least 0.7
• TOFR of 0.9 has now been shown to be necessary prior to extubation if the airway is to be protected completely.
![Page 57: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/57.jpg)
Why Fade ?
Fade may be due to a prejunctional efect of nondepolar-izing relaxants
• that reduces the amount of ACh in the nerve terminal available for release during stim-ulation (blockade of ACh mobilization).
Adequate clinical recovery correlates well with the absence of fade.
• sustained tetanic stimulation or double-burst stimulation than following a train-of-four pattern or repeated twitches, • the first two patterns are the preferred methods for determining adequacy of recovery from a nondepolarizing block.
Because fade is more obvious during
![Page 58: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/58.jpg)
Tetanic Stimulation
Most sensitive form of neuromuscular stimulation.
• Loss of contraction during tetanic stimulation, known as tetanic fade , is a sensitive indicator of residual neuromuscular blockade.
Repetitive high-frequency stimulation frequencies of 50–100 Hz are applied to a peripheral nerve to detect even minor degrees of residual neuromuscular block
• Tetanic fade may be present when the twitch response is normal.
Tetanic rates of stimulation may be applied under Anaesthesia,….. But in the awake patient painful
![Page 59: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/59.jpg)
Post-Tetanic Potentiation or Facilitation
Assess more profound degrees of neuro-muscular block produced by non-depolarizing neuromuscular blocking agents.
• The number of twitches observed is inversely related to the degree of blockade.
If a single twitch stimulus is applied to the nerve with little or no neuro-muscular response,…. >But after a 5 s delay a burst of 50-hz tetanus is given for 5 s….,> The effect of a further twitch stimulus 3 s later is enhanced
Profound block, ….The effect of repeated single twitches applied after the tetanus until the response disappears can be counted; this is termed the …..Post-tetanic count
![Page 60: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/60.jpg)
![Page 61: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/61.jpg)
Why postte-tanic potentiation ?
ability of tetanic stimulation during a par-tial nondepolarizing block to increase the evoked response to a subsequent twitch is termed postte-tanic potentiation.
Due to a transient increase in ACh mobilization following tetanic stimulation
![Page 62: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/62.jpg)
Double-Burst Stimulation (DBS)
More accurate assessment of residual block by visual or tactile means than fade of the TOF response
Application of two or three short bursts of 50-hz tetanus,…. Each comprising two or three impulses ….Separated by a 750-ms interval. ……Each impulse lasts for 0.2 ms
![Page 63: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/63.jpg)
Three short (0.2 ms) high-frequency stimulations separated by a 20-ms interval (50 Hz) and followed ……750 ms later by
• two (DBS 3,2 ) or • three (DBS 3,3 ) additional impulses.
![Page 64: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/64.jpg)
Recording the Response
1. Visual and tactile evaluation
• is the easiest and least expensive way to assess the response to electrical stimulation applied to a peripheral nerve
• The disadvantage of this technique is the• subjective nature of its interpretation (present or absent, weak or strong)
![Page 65: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/65.jpg)
2. Measurement of force-Mechanomyography
• using a force transducer provides accurate assessment (quantitative or objective) of the response elicited by electrical stimulation of a peripheral nerve.
3. Electromyography
• measures the electrical rather than mechanical response of the skeletal muscle.
4. Accelerometry devices
• are usually attached to the thumb• a digital readout is obtained • The use of accelerometry is helpful in the diagnosis of residual paralysis
![Page 66: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/66.jpg)
Choice of Muscle
Muscles do not respond in a uniform fashion to NMBAs…..differences in
• time to onset• maximum blockade• duration of action
muscles of physiologic importance
• abdominal muscles during surgery• upper airway muscles postoperatively• A common strategy is to monitor one site adductor pollicis…Usually
![Page 67: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/67.jpg)
1. Adductor pollicis muscle
• Supplied by the ulnar nerve • This muscle is relatively sensitive to nondepolarizing muscle relaxants(blocked SOONER than respiratory)• During recovery, it is blocked more than some respiratory muscles such as the diaphragm and laryngeal
adductors(recover LATE than respiratory)
2. Muscles surrounding the eye
• Innervated by the facial nerve • A. The response of the orbicularis oculi over the eyelid is similar to that of the adductor pollicis.• B. The response the eyebrow (corrugator supercilii) parallels the response of the laryngeal adductors. • (Onset is more rapid and recovery is sooner than at the adductor pollicis.) This response is useful for predicting intubating
conditions.
![Page 68: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/68.jpg)
Clinical Applications
1. Monitoring Onset.
• After induction ,determine the time for tracheal intubation• (maximum relaxation of laryngeal and respiratory muscles).
• Single-twitch stimulation is often used to monitor the onset of neuromuscular blockade.
2. Monitoring Surgical Relaxation
• Adequate surgical relaxation is usually present when fewer than 2 or 3 visible twitches of the TOF are observed in response to stimulation of the adductor pollicis muscle
![Page 69: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/69.jpg)
3. Monitoring Recovery.
• Complete return of neuromuscular function should be achieved before extubation • Respiratory and upper airway function does not return to normal unless the TOF ratio at the
adductor pollicis muscle is ≥0.9.• Anticholinesterase agents should be given only when four twitches are visible • The presence of spontaneous breathing is not a sign of adequate neuromuscular recovery.
• (The diaphragm recovers earlier than upper airway muscles that recover in parallel with the adductor pollicis muscle.)
• the visual or tactile evaluation of TOF response is not reliable for ruling out residual blockade
![Page 70: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/70.jpg)
Depolarizing NMBA
(Suxamethonium)
![Page 71: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/71.jpg)
SUCCINYLCHOLINE
Succinylcholine quaternary ammonium compound—also called diacetylcholine or suxamethonium—
• consists of two joined ACh molecules
only depolarizing relaxant now available in clinical practice is succinylcholine.
• Decamethonium was used clinically in the UK for many years
![Page 72: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/72.jpg)
![Page 73: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/73.jpg)
![Page 74: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/74.jpg)
Mechanism of action
Phase i block
Phase ii block
![Page 75: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/75.jpg)
Metabolism & Excretion
Rapid onset of action (30–60 s) and
• Small volume of distribution due to its very low lipid solubility• Relative overdose that is usually administered.
Short duration of action (usually less than 10 min).
• 10% of the drug is excreted in the urine; there is very little metabolism in the liver although some breakdown by non-specific esterases occurs in the plasma.
In circulation.....Rapidly metabolized by pseudocholinesterase into succinylmonocholine.
![Page 76: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/76.jpg)
Causes of prolonged effect of Suxamethonium
Limited duration of action....Recovery from neuromuscular block may start to occur within 3 min and is complete within 12–15 min.
• Drug levels fall in blood, succinylcholine molecules diffuse away from the neuromuscular junction
Can be prolonged by
• High doses• Infusion of succinylcholine• Abnormal metabolism• Hypothermia, • Reduced pseudocholinesterase levels,• Genetically aberrant enzyme
![Page 77: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/77.jpg)
Decreased level of pseudocholinesterase
Reduced pseudocholinesterase levels...Generally produce only modest prolongation of succinylcholine’s actions (2–20 min).
• Pregnancy, • Liver disease, • Renal failure, and• Carcinomatosis and starvation, • Also because of reduced enzyme synthesis• Hypothyroidism.,• Cardiopulmonary bypass• Plasmapheresis
Certain drug therapies
• Echothiophate......Organophosphate use for glaucoma • Neostigmine ,pyridostigmine....Cholinesterase inhibitors • Phenelzine.....Monoamine oxidase inhibitor • Cyclophosphamide....Anti neoplastic • Metoclopramide...Antiemetic & prokinetic • Esmolol...Beta blocker • Pancuronium....Non depolarizing nmba • Oral contraceptives
![Page 78: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/78.jpg)
Inherited factorsatypical/abnormal
pseudocholinesterse
Structure of plasma cholinesterase is determined genetically, by autosomal genes,
• One in 25-30 patients of european extraction is a heterozygote with one normal and one abnormal (atypical) pseudocholinesterase gene, resulting in a slightly prolonged block (20–30 min)
1.Heterozygote for the atypical gene
• Will have a very long blockade eg, 4–8 h
2.Homozygous atypical pseudocholinesterse gene.....1 in 3000 patients have two copies of the abnormal gene (homozygous atypical) that produce an enzyme with little or no affinity for succinylcholine.
![Page 79: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/79.jpg)
Types of Homozygous Pseudocholinesterse
1.The dibucaine-resistant (variant) allele
• Which produces an enzyme with 1/100 of normal affinity for succinylcholine, is the most common.
2.Fluoride-resistant
3.Silent (no activity) alleles.
![Page 80: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/80.jpg)
Measurement of Atypical Pseudocholinesterse
1.Qunatitative....determined in the laboratory quantitatively in units per liter (a minor factor)
2.Qualitative.......qualitatively by dibucaine number (the major factor)
![Page 81: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/81.jpg)
Dibucaine NumberDibucaine, a local anesthetic, inhibits normal pseudocholinesterase activity by 80%, but inhibits atypical enzyme activity by only 20%.
Serum from an individual who is heterozygous for the atypical enzyme is characterized by an intermediate 40% to 60% inhibition
percentage of inhibition of pseudocholinesterase activity is termed the dibucaine number
![Page 82: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/82.jpg)
Method for detecting structurally abnormal cholinesterase.
![Page 83: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/83.jpg)
When plasma sample should be taken?
Plasma cholinesterase activity is reduced by the presence of succinylcholine, a plasma sample to measure the patient’s cholinesterase activity should not be taken for several days after prolonged block has been experienced, by which time new enzyme has been synthesized.
![Page 84: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/84.jpg)
Detection of geno type of Atypical Pseudocholinesterse ?
![Page 85: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/85.jpg)
Management of succinylcholine Apnoea
This condition is not life-threatening, but the risk of awareness is considerable
• especially after the end of surgery, when the anaesthetist, who may not yet have made the diagnosis, is attempting to waken the patient.
Anaesthesia must be continued until full recovery from neuromuscular block is demonstrable.
• In such patients, non-specific esterases(10% metabolism) gradually clear the drug from plasma.
source of cholinesterase, such as fresh frozen plasma, should be administered
![Page 86: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/86.jpg)
![Page 87: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/87.jpg)
Drug Interactions
![Page 88: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/88.jpg)
Drug interaction sepcial considerations
1.Cholinesterase Inhibitors……markedly prolong a depolarizing phase I block by two mechanisms.
• 1. inhibiting acetylcholinesterase....higher ACh concentration at the nerve terminal, which intensifies depolarization
• 2.inhibiting pseudocholinesterase....reduce the hydrolysis of succinylcholine
Example
• Organophosphate pesticides, for ......irreversible inhibition of acetylcholinesterase and can prolong the action of succinylcholine by 20–30 min.
• Echothiophate eye drops......can markedly prolong succinylcholine
![Page 89: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/89.jpg)
2. Nondepolarizing Relaxants
small doses of nondepolarizing relaxants
• antagonize a depolarizing phase I block. ....drugs occupy some ACh receptors,.....so• partial prevention of depolarization by succinylcholine
If enough depolarizing agent is administered...... to develop a phase II block,
• then a nondepolarizer will potentiate paralysis.
![Page 90: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/90.jpg)
Dosage & Storage
usual adult dose of succinylcholine for intubation is 1–1.5 mg/kg intravenously.
• Doses as small as 0.5 mg/kg will oft en provide acceptable intubating conditions if a defasciculating dose of a nondepolarizing agent is not used.
Repeated small boluses (10 mg) or a succinylcholine drip (1 g in 500 or 1000 mL, titrated to eff ect) can be used during surgical procedures that require brief but intense paralysis
• ENT procedures...endoscopy• Neuromuscular function should be frequently monitored with a nerve stimulator to prevent
overdosing and to watch for phase II block.
![Page 91: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/91.jpg)
Pediatric patients are often need greater than for adults.....
• Suxamethonium not lipid soluble & infants and neonates have a larger extracellular space than adults
Intramuscularly to children
• A dose as high as 4–5 mg/kg does not always produce complete paralysis.
Storage...
• Stored under refrigeration (2–8°C), and should be used within 14 days after removal from refrigeration and exposure to room temperature.
![Page 92: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/92.jpg)
Side Effects & Clinical Considerations
Succinylcholine is still useful for rapid sequence induction and for short periods of intense paralysis
succinylcholine is considered relatively contraindicated in the routine management of children and adolescent
patients...undiagnosed myopathies
Most clinicians have also abandoned the routine use of succinylcholine for adults
![Page 93: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/93.jpg)
![Page 94: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/94.jpg)
1.Cardiovascular
Suxamethonium acts cholinergic ach receptors in addition to those at the neuromuscular junction
• Entire parasympathetic nervous system and• Parts of the sympathetic nervous system
• Sympathetic ganglions• Adrenal medulla• Sweat glands
![Page 95: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/95.jpg)
Stimulation of nicotinic receptors in parasympathetic and sympathetic ganglia, and muscarinic receptors in the sinoatrial node of the heart......complex effects
increase or decrease blood pressure and heart
rate.
Low doses of succinylcholine can produce negative chronotropic and
inotropic effects
higher doses usually increase heart rate and contractility and elevate circulating catecholamine
levels
![Page 96: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/96.jpg)
Children are particularly susceptible to profound bradycardia following administration of succinylcholine.
• succinylmonocholine, sensitizes muscarinic cholinergic receptors in the sinoatrial node• Intravenous atropine (0.02 mg/kg in children, 0.4 mg in adults) is normally given
prophylactically to children prior to the first and subsequent doses in adults.
in adults Bradycardia will sometimes occur when a second bolus of succinylcholine is administered approximately 3–8 min after the first dose
arrhythmias.....nodal bradycardia and ventricular ectopy
![Page 97: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/97.jpg)
B. Fasciculations•Visible motor unit contractions called fasciculation
Onset of paralysis by succinylcholine.....
•Pretreatment with a small dose of nondepolarizing relaxant...ThenPrevented by
•(1.5 mg/kg)Larger dose of
succinylcholine is required
•Young children and •Elderly patients.
Not observed in
![Page 98: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/98.jpg)
C. Hyperkalemia•to increase serum potassium by 0.5 mEq/L.•insignificant in patients with normal baseline potassium levels•can be life- threatening in patients with preexisting hyperkalemia.
succinylcholine-induced
depolarization
•can prove to be quite refractory to routine cardiopulmonary resuscitation•requiring calcium, insulin, glucose, bicarbonate, and even cardiopulmonary bypass
Hyperkalemic cardiac
arrest
![Page 99: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/99.jpg)
Conditions causing susceptibility to succinylcholine-induced hyperkalemia
Burn injury
Massive trauma
Severe intraabdominal infection
Spinal cord injury
Encephalitis
Stroke
Guillain-Barré syndrome
Severe Parkinson’s disease
Tetanus
Prolonged total body immobilization
Ruptured cerebral aneurysm
Polyneuropathy
Closed head injury
Hemorrhagic shock with metabolic acidosis Myopathies (eg, Duchenne’s dystrophy)
![Page 100: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/100.jpg)
![Page 101: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/101.jpg)
Mechanism of hyperkalemia
![Page 102: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/102.jpg)
![Page 103: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/103.jpg)
D. Muscle Pains•Rocuronium (0.06–0.1 mg/kg) prior to succinylcholine has been reported to be effective
Increased incidence of postoperative
myalgia…..Prevention by
•Myoglobinemia and increases in serum creatine kinase can be detected following administration of succinylcholine
Myalgias are theorized to be due to the initial
unsynchronized contraction of muscle
groups
•Use of nonsteroidal antiinfl ammatory drugs may reduce the incidence and severity of myalgias.
Treatment
![Page 104: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/104.jpg)
E. Intragastric Pressure Elevation
Abdominal wall muscle fasciculations
offset by an increase in lower esophageal sphincter tone.
no evidence that the risk of gastric reflux or pulmonary aspiration is increased by succinylcholine
![Page 105: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/105.jpg)
F. Intraocular Pressure Elevation
Extraocular muscle.....multiple motor end-plates on each cell.
• no evidence that succinylcholine leads to worsened outcome in patients with “open” eye injuries
Prolonged membrane depolarization and contraction of extraocular muscles
• not always prevented by pretreatment with a nondepolarizing agent.
transiently raise intraocular pressure and theoretically could compromise an injured eye
Prevention
![Page 106: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/106.jpg)
G. Masseter Muscle Rigidity
•Some difficulty .... In opening the mouth
Transiently increases muscle
tone in the masseter muscles.
•Premonitory sign of malignant hyperthermia
Marked increase in tone preventing laryngoscopy is abnormal .......
![Page 107: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/107.jpg)
H. Malignant Hyperthermia
Acute hypermetabolic disorder of skeletal muscle.....
• Pharmacogenetic pathology• Potent volatile anaesthetics with suxamethonium
Succinylcholine is a potent triggering agent in patients susceptible
no need to avoid use of succinylcholine in patients with NMS.
![Page 108: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/108.jpg)
I. Generalized Contractions
Patients afflicted with myotonia may develop myoclonus after administration of succinylcholine.
Patients with reduced levels of normal pseudocholinesterase may have a longer than normal duration of action,
Whereas patients with atypical pseudocholinesterase will experience markedly prolonged paralysis.
![Page 109: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/109.jpg)
J. Prolonged Paralysis
Patients with reduced levels of normal pseudocholinesterase may have a longer than normal duration of action,
Whereas patients with atypical pseudocholinesterase will experience markedly prolonged paralysis.....Sux. apnea
![Page 110: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/110.jpg)
K. Intracranial Pressure
Succinylcholine may lead to an activation of the electroencephalogram
Slight increases in cerebral blood flow and intracranial pressure
Fasciculations stimulate muscle stretch receptors, which subsequently increase cerebral activity.
![Page 111: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/111.jpg)
Prevention
• Increase in intracranial pressure can be attenuated by maintaining good airway control and instituting hyperventilation.
• Pretreating with a nondepolarizing muscle relaxant • Administering intravenous lidocaine (1.5–2.0 mg/kg) 2–3 min prior to intubation.
Succinylcholine is NOT contraindicated for rapid sequence induction of patients with intracranial mass lesions or other causes of increased intracranial pressure....If benefits overweights
![Page 112: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/112.jpg)
L. Histamine Release
Slight increase in histamine after suxamethonium administration
![Page 113: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/113.jpg)
Nondepolarizing Muscle Relaxants
![Page 114: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/114.jpg)
1.Unique Pharmacological Characteristics
classified as
• benzylisoquinolinium, • steroidal, or other compounds.
In general, steroidal compounds can be vagolytic, but this property is most notable with pancuronium
Benzylisoquinolines tend to release histamine
Because of structural similarities, an allergic history to one muscle relaxant strongly suggests the possibility of allergic reactions to other muscle relaxants, particularly those in the same chemical class.
![Page 115: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/115.jpg)
A. Suitability for Intubation
None of the currently available nondepolarizing muscle relaxants equals succinylcholine
• either a larger dose or • a priming dose.
onset of nondepolarizing relaxants can be quickened by using
ED 95 of any drug ....is the eff ective dose of a drug in 95% of individuals
But for neuromuscular blockers ED95 is.... the dose that produces 95% twitch depression in 50% of individuals.
![Page 116: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/116.jpg)
larger intubating dose speeds onset, it exacerbates side eff ects and prolongs the duration of blockade.
• For example, a dose of 0.15 mg/kg of pancuronium may produce intubating conditions in 90 sec, but at the cost of more pronounced tachycardia—and a block that may be irreversible (by neostigmine) for more than 60 min
![Page 117: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/117.jpg)
Why potent NMBA has slow onset of action? What is priming dose ?
General rule,..... The more potent the nondepolarizing muscle relaxant, the slower its speed of onset
• More the no. Of molecules available at receptors for effect …..More rapid onset• Less number of molecules required will be available at receptors to get the response…..In case of
potent drug
Priming doses...Giving 10% to 15% of the usual intubating dose 5 min before induction will occupy enough receptors so that paralysis will quickly follow when the balance of relaxant is administered.
• Can produce conditions suitable for intubation as soon as 60 sec following administration of rocuronium or 90 sec following administration of other intermediate-acting nondepolarizers
![Page 118: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/118.jpg)
Priming dose.....Not usually lead to clinically significant paralysis, which requires that 75% to 80% of the receptors be blocked (a neuromuscular margin of safety).
• Distressing dyspnea, diplopia, or dysphagia; • In such instances, the patient should be reassured• Induction of anesthesia should proceed without delay.• Oxygen desaturation in patients with marginal pulmonary reserve
Side effects of priming dose...
Muscle groups vary in their sensitivity to muscle relaxants..Laryngeal muscle recover first
![Page 119: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/119.jpg)
B. Suitability for Preventing Fasciculations
To prevent fasciculations and myalgias, 10% to 15% of a nondepolarizer intubating dose.........5 min before succinylcholine.
Shortly before succinylcholine, myalgias, but not fasciculations, will be inhibited.
Tubocurarine and rocuronium have been most popular for precurarization
![Page 120: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/120.jpg)
C. Maintenance Relaxation
Following intubation, muscle paralysis may need to be maintained
• To facilitate surgery, (eg, abdominal operations), • To permit a reduced depth of anesthesia, • To control ventilation
Prevention of over- and under dosing ...... to reduce the likelihood of serious residual muscle paralysis in the recovery room...
• Intermittent boluses or • Continuous infusion
Use nerve stimulator for monitoring neuromuscular function
Techniques of maintenance doses...Should be guided by the nerve stimulator and clinical signs
![Page 121: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/121.jpg)
D. Potentiation by Inhalational Anesthetics
Volatile agents decrease nondepolarizer dosage requirements by at least 15%
• Inhalational anesthetic (desflurane > sevofl urane > isofl urane and enfl urane > halothane > N 2 O/O 2 / narcotic)
• Muscle relaxant employed (pancuronium > vecuronium and atracurium)
Postsynaptic augmentation depends on
![Page 122: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/122.jpg)
E. Potentiation by Other Nondepolarizers
Synergistic
• combinations of nondepolarizers produce a greater than additive (synergistic) neuromuscular blockade.
Additive
• Th e lack of synergism (ie, the drugs are only additive) by closely related compounds (eg, vecuronium and pancuronium)
![Page 123: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/123.jpg)
F. Autonomic Side Effects
Nondepolarizers differ in their relative effects on nicotinic and muscarinic cholinergic receptors.
• Reducing the ability of the sympathetic nervous system to increase heart contractility and rate in response to hypotension and other intraoperative stresses....Eg,tubocurarine and, to a lesser extent, metocurine
Autonomic ganglion blockade
• Tachycardia.Eg,pancuronium
Block vagal muscarinic receptors in the sinoatrial node....
Newer nondepolarizing relaxants, including atracurium, cisatracurium, vecuronium, and rocuronium, are devoid of significant autonomic effects
![Page 124: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/124.jpg)
G. Histamine Release
Histamine release from mast cells
• bronchospasm • skin flushing • hypotension
atracurium and mivacurium are capable of triggering histamine release, particularly at higher doses
• Slow injection rates • H 1 and H 2 antihistamine pretreatment
Prevention
![Page 125: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/125.jpg)
H. Hepatic Clearance
Only pancuronium and vecuronium are metabolized to any significant degree by the liver.
• Active metabolites likely contribute... clinical effect.
Vecuronium and rocuronium depend heavily on biliary excretion.
• prolongs pancuronium and rocuronium blockade• less eff ect on vecuronium, • no eff ect on pipecuronium.
liver failure
• Atracurium,cisatracurium &mivacurium, although extensively metabolized, depend on extrahepatic mechanisms
Extra hepatic metabolism
Severe liver disease....decrease in pseudocholinesterase levels may slow the metabolism of mivacurium.
![Page 126: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/126.jpg)
I. Renal ExcretionAction is prolonged in patients with renal failure......
• Doxacurium, pancuronium, vecuronium, and pipecuronium are partially excreted by the kidneys,
Independent of kidney function.
• Elimination of atracurium, cisatracurium, mivacurium, and rocuronium
![Page 127: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/127.jpg)
![Page 128: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/128.jpg)
![Page 129: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/129.jpg)
2.General Pharmacological Characteristics of Non depolarizing MNBA
![Page 130: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/130.jpg)
A. Temperature Hypothermia prolongs blockade by 1.decreasing metabolism
(eg, mivacurium, atracurium, and cisatracurium) and
2.delaying excretion (eg, pancuronium and vecuronium).
![Page 131: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/131.jpg)
B. Acid–Base Balance
Respiratory acidosis potentiates the blockade of most nondepolarizing relaxants and antagonizes its reversal.
due to coexisting alterations in extracellular pH, intracellular pH,
electrolyte concentrations, or structural diff erences between drugs
![Page 132: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/132.jpg)
C. Electrolyte Abnormalities
Hypokalemia and hypocalcemia ....augment a nondepolarizing block.
Th e responses with hypercalcemia are ......unpredictable.
Hypermagnesemia..... potentiates a nondepolarizing blockade by competing with calcium at the motor end-plate.
![Page 133: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/133.jpg)
D. Age Neonates have an increased sensitivity to
nondepolarizing relaxants because of their immature neuromuscular junctions
does not necessarily decrease dosage requirements, as the neonate’s greater extracellular space provides a larger volume of distribution.
![Page 134: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/134.jpg)
Additional considerations in special populations.
![Page 135: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/135.jpg)
E. Drug Interactions
many drugs augment nondepolarizing blockade multiple sites of interaction:
prejunctional structures postjunctional cholinergic receptors
muscle membranes
![Page 136: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/136.jpg)
![Page 137: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/137.jpg)
F. Concurrent Disease
neurological or muscular disease can have profound eff ects on an individual’s response to muscle relaxants
Cirrhotic liver disease and chronic renal failure increased volume of distribution and a lower plasma
concentration for a given dose of water-soluble drugs, such as muscle relaxants
drugs dependent on hepatic or renal excretion may demonstrate prolonged clearance
greater initial (loading) dose—but smaller maintenance doses
![Page 138: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/138.jpg)
![Page 139: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/139.jpg)
G. Muscle Groups The onset and intensity of blockade vary among muscle groups.
differences in blood flow, distance from the central circulation, or
different fiber types. choice of muscle relaxant.
diaphragm, jaw, larynx, and facial muscles (orbicularis oculi) respond to and recover from muscle relaxation sooner than the thumb.
Glottic musculature is also quite resistant to blockade, as is often confirmed during laryngoscopy.
intubating conditions are usually associated with visual loss of the orbicularis oculi twitch response.
However...Wide variability in sensitivity to nondepolarizing muscle relaxants is oft en encountered in clinical practice
![Page 140: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/140.jpg)
INDIVIDUAL NON-DEPOLARIZINGNMBAs
![Page 141: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/141.jpg)
![Page 142: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/142.jpg)
ATRACURIUMPhysical structure
• Atracurium has a quaternary group
Benzylisoquinoline structure
• Is responsible for its unique method of degradation.
Hofmann degradation may be considered as a ‘safety net’ in the sick patient with impaired liver or renal function
• A mixture of 10 stereoisomers.
![Page 143: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/143.jpg)
Metabolism & Excretion
Extensively metabolized …automatic degradation….Ph & temperature dependent
Pharmacokinetics are independent of renal and hepatic function
Less than 10% is excreted unchanged by renal and biliary routes.
![Page 144: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/144.jpg)
Two separate processes are responsible for metabolism
• nonspecifi c esterases, not by acetylcholinesterase or pseudocholinesterase
A. Ester Hydrolysis
• spontaneous nonenzymatic chemical breakdown occurs at • physiological pH and • temperature.
B. Hofmann Elimination
![Page 145: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/145.jpg)
Dosage & StorageOnset....2.0 - 2.5 mins
• 0.5 mg/kg ...intravenously for intubation
Intubation
• 0.25 mg/kg initially, then • in incremental doses of 0.1 mg/kg every 10–20 min
After succinylcholine, intraoperative relaxation
• 5–10 mcg/kg/min can effectively replace intermittent boluses.
infusion
• available as a solution of 10 mg/ mL• It must be stored at 2–8°C • loses 5% to 10% of its potency for each month it is exposed to room temperature. • At room temperature, it should be used within 14 days
Storage & availability
![Page 146: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/146.jpg)
Side Effects & Clinical Considerations
Dose-dependent histamine release ...Significant at doses above 0.5 mg/kg.
• Unusual unless doses in excess of 0.5 mg/kg• Transient drop in systemic vascular resistance and• Increase in cardiac index independent of any histamine release.• Prevention
• A slow rate of injection minimizes these eff ects.
1.Hypotension and tachycardia
![Page 147: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/147.jpg)
2.Bronchospasm
• Avoided in asthmatic patients. • Severe bronchospasm is occasionally seen in patients without a history of
asthma
3.Laudanosine toxicity
• Tertiary amine, is a breakdown product of atracurium’s hofmann elimination • Associated with central nervous system excitation,• Resulting in elevation of the minimum alveolar concentration • Precipitation of seizures.• Laudanosine is metabolized by the liver and excreted in urine and bile.
![Page 148: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/148.jpg)
4.Temperature and pH Sensitivity
• Hoffman degredation... pH & temperature dependant • duration of action can be markedly prolonged by hypothermia and to a
lesser extent by acidosis.
5.Chemical Incompatibility
• Atracurium will precipitate as a free acid if it is introduced into an intravenous line containing an alkaline solution such as thiopental.
![Page 149: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/149.jpg)
6.Allergic Reactions
• Histamine release....local wheal and flare around the injection site• Anaphylactoid reactions ... but rare
• Proposed mechanisms include • direct immunogenicity • acrylate-mediated immune activation. • IgE-mediated antibody reactions directed against substituted ammonium compounds...muscle
relaxants, • Reactions to acrylate, a metabolite of atracurium and a structural component of some dialysis membranes
![Page 150: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/150.jpg)
CISATRACURIUM
Physical Structure
• Cisatracurium is a stereoisomer of atracurium • four times more potent. • Atracurium contains approximately 15% cisatracurium.
![Page 151: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/151.jpg)
Metabolism & Excretion
• Hofmann elimination ....• degradation in plasma at physiological pH
and temperature …. organ-independent .• metabolites (a monoquaternary acrylate
and laudanosine) have no neuromuscular blocking eff ects
• Nonspecific esterases are not involved in the metabolism of cisatracurium.
• Metabolism and elimination are independent of renal or liver failure.
![Page 152: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/152.jpg)
Dosage & Storage
• intubating dose .......0.1–0.15 mg/kg within 2 min and results in muscle blockade of intermediate duration.
• maintenance infusion rate ranges from 1.0–2.0 mcg/kg/min.• Refrigeration (2–8°C)
• used within 21 days after removal from refrigeration and exposure to room temperature.
![Page 153: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/153.jpg)
Side Eff ects & Clinical Considerations
• does not produce a consistent, dose-dependent increase in plasma histamine levels
• does not alter heart rate or blood pressure, nor does it produce autonomic effects
• Cisatracurium shares with atracurium the• production of laudanosine, • pH and temperature sensitivity & chemical incompatibility.
![Page 154: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/154.jpg)
ROCURONIUMPhysical Structure
• monoquaternary steroid • analogue of vecuronium
rapid onset of action.
• greater number of drug molecules may reach the postjunctional receptors within the first few circulations.......faster development of neuromuscular block
6-8 times less potent than vecuronium but has approximately the same molecular weight.......
![Page 155: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/155.jpg)
Metabolism & Excretion…..
• no metabolism and is eliminated primarily by the liver and slightly by the kidneys.
Duration of action....
• prolonged by severe hepatic failure and pregnancy• Elderly patients may experience a prolonged duration of action due to decreased liver mass. • Not significantly affected by renal disease• does not have active metabolites....better choice than vecuronium in the patient requiring prolonged infusions in the
intensive care unit
![Page 156: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/156.jpg)
Dosage
• Rocuronium is less potent than most other steroidal muscle relaxants (potency seems to be inversely related to speed of onset)
• for intubation........0.45–0.9 mg/kg intravenously and 0.15 mg/kg boluses for maintenance. • A lower dose of 0.4 mg/kg may allow reversal as soon as 25 min after intubation.• Intramuscular rocuronium (1 mg/kg for infants; 2 mg/kg for children) .....for intubation ...after
3–6 min..... can be reversed aft er about 1 hr.• infusion requirements for rocuronium range from 5–12 mcg/kg/min.
![Page 157: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/157.jpg)
Side Effects & Clinical Considerations
• Rocuronium (at a dose of 0.9–1.2 mg/kg) has an onset of action that approaches succinylcholine (60–90 s), making it a suitable • alternative for rapid-sequence inductions, but at the cost of a much longer duration of action
• Rocuronium (0.1 mg/kg) has been shown to be a rapid (90 s) and effective agent ) for precurarization prior to administration of succinylcholine• decreased fasciculations and postoperative myalgias
• drug stimulates little histamine release or cardiovascular disturbance, although in high doses it has a mild vagolytic property• Anaphylactic reactions are more common after rocuronium than after any other aminosteroid neuromuscular blocking
drug. ...at a similar rate to anaphylactic reactions to atracurium and mivacurium.
![Page 158: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/158.jpg)
PANCURONIUMPhysical Structure
• steroid ring on which two modifi ed ACh molecules are positioned (a bisquaternary relaxant).
Metabolism & Excretion
• metabolized (deacetylated) by the liver to a limited degree. • Its metabolic products have some neuromuscular blocking activity. • Excretion is primarily renal (40%), although some of the drug is cleared by the bile (10%)
![Page 159: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/159.jpg)
renal failure......
• elimination of pancuronium is slowed and neuromuscular blockade is prolonged
cirrhosis.......
• may require a larger initial dose due to an increased volume of distribution but have reduced maintenance requirements because of a decreased rate of plasma clearance.
![Page 160: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/160.jpg)
Dosage
• intubation..... 0.08–0.12 mg/kg of pancuronium provides adequate relaxation in 2–3 min.
• Intraoperative relaxation .... 0.04 mg/kg initially followed every 20–40 min by 0.01 mg/kg.
Storage
• available as a solution of 1 or 2 mg/mL • stored at 2–8°C but • stable for up to 6 months at normal room temperature.
![Page 161: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/161.jpg)
Side Effects & Clinical Considerations
A. Hypertension and Tachycardia
• vagal blockade • sympathetic stimulation. • ganglionic stimulation, • catecholamine release from adrenergic nerve endings• decreased catecholamine reuptake
Large bolus doses of pancuronium.....caution to patients in whom an increased heart rate would be particularly detrimental
• (eg, coronary artery disease, hypertrophic cardiomyopathy, aortic stenosis)
![Page 162: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/162.jpg)
B. Arrhythmias
• ventricular arrhythmias...due to• Increased atrioventricular conduction and• catecholamine release• pancuronium, tricyclic antidepressants and halothane...arrhythmogenic
C. Allergic Reactions
• hypersensitive to bromides may exhibit allergic reactions to pancuronium (pancuronium bromide).
![Page 163: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/163.jpg)
VECURONIUMPhysical Structure
• pancuronium minus a quaternary methyl group (a monoquaternary relaxant). • alters side effects without affecting potency.
Metabolism & Excretion
• metabolized to a small extent by the liver.
excretion......
• primarily on biliary excretion and secondarily (25%) on renal
shorter elimination half-life and more rapid clearance compared with pancuronium
![Page 164: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/164.jpg)
Long-term administration in ICU.....prolonged neuromuscular blockade (up to several days)
• from accumulation of its active 3-hydroxy metabolite, changing drug clearance, and in some patients..... polyneuropathy.
• Risk factors ۔۔۔ gender, renal failure, long-term or high-dose corticosteroid therapy, and
Tolerance to non depolarizing muscle relaxants can also develop after long term use.
• equipotent with pancuronium, and the intubating dose is 0.08–0.12 mg/kg.• maintenance of relaxation. 0.04۔۔ mg/kg initially followed by increments of 0.01 mg/kg every 15–20 min provides intraoperative relaxation. • infusion of 1–2 mcg/kg/min produces good
Dosage
![Page 165: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/165.jpg)
Women seem to be approximately 30% more sensitive than men to vecuronium, .....(this has also been seen with pancuronium and rocuronium).
• cause .......gender-related diff erences in fat and muscle mass, protein binding, volume of distribution, or metabolic activity.
Side Effects & Clinical Considerations
• 1.Cardiovascular• No significant cardiovascular effects. • Potentiation of opioid-induced bradycardia .
• 2.Liver Failure• dependent on biliary excretion, • duration of action of vecuronium is usually not signifi cantly prolonged in patients with cirrhosis unless doses greater than 0.15 mg/kg are given .
![Page 166: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/166.jpg)
![Page 167: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/167.jpg)
NEWER MUSCLE
RELAXANTS
![Page 168: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/168.jpg)
GantacuriumNew class of nondepolarizing neuromuscular blockers called chlorofumarates.
• rapid formation of inactive cysteine adduction product and • ester hydrolysis
It is provided as a lyophilized powder, because it is not stable as an aqueous solution
ultrashort duration of action, similar to that of succinylcholine.
undergoes nonenzymatic degradation by two chemical mechanisms:
![Page 169: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/169.jpg)
Dosage
• dose of 0.2 mg/kg (ED 95 ), the onset of action has been estimated to be 1-2 min, with a duration of blockade similar to that of succinylcholine.
Its clinical duration of action ranged from 5-10 min;
• edrophonium • exogenous cysteine.
recovery can be accelerated by
• histamine release were observed following the use of three times the ED 95 dosage.
Cardiovascular effects
![Page 170: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/170.jpg)
AV002 (CW002) is another investigational nondepolarizing agent.
It is a benzylisoquinolinium fumarate ester-based compound
intermediate duration of action
metabolism and elimination similar to that of gantacurium.
![Page 171: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/171.jpg)
OTHER RELAXANTS(Historical interest)
no longer manufactured or not clinically used
• the first muscle relaxant used clinical• Histamine release • produce or exacerbate bronchospasm• often produced hypotension and tachycardia through histamine release• ability to block autonomic ganglia . • Tubocurarine is not metabolized significantly, • elimination is primarily renal and secondarily biliary.
Tubocurarine
![Page 172: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/172.jpg)
Metocurine
• shares many of the side effects of tubocurarin• primarily dependent on renal function for elimination. • Patients allergic to iodine (eg, shellfish allergies) could exhibit hypersensitivity to metocurarine.... contain iodide.
Gallamine
• the most potent vagolytic properties of any relaxant, • entirely dependent on renal function for elimination.
Alcuronium
• long-acting nondepolarizer • mild vagolytic properties • primarily dependent on renal function for elimination
Rapacuronium
• has a rapid onset of action, • minimal cardiovascular side eff ects, and a• short duration of action. • withdrawn by the manufacturer following multiple reports of serious bronchospasm, Histamine release may have been a factor.
![Page 173: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/173.jpg)
Decamethonium
• An older depolarizing agent
Mivacurium
• Benzylisoquinolinium derivative, • Metabolized by pseudocholinesterase• Duration of action may be prolonged in pathophysiological states that result in low pseudocholinesterase levels. • Intubating dose is 0.2 mg/kg, ... infusion rate being 4-10 mcg/kg/ min. • Releases histamine to about the same degree as atracurium; the • Cardiovascular effects can be minimized by slow injection.• Mivacurium is useful particularly for surgical procedures requiring muscle relaxation in which even atracurium and vecuronium seem too long-acting, and when it is desirable to avoid the side-effects of succinylcholine,
tonsillectomy• E.G. For bronchoscopy, oesophagoscopy, laparoscopy or tonsillectomy
![Page 174: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/174.jpg)
Doxacurium
• Potent long-acting benzylisoquinolinium compound • Primarily eliminated by renal excretion. • Intubating conditions are achieved in 5 min with 0.05 mg/ kg. • Devoid of cardiovascular and histamine-releasing side eff ects.
Pipecuronium
• A bisquarternary steroidal compound similar to pancuronium• Without the vagolytic eff ects. • Onset and duration of action are also similar to pancuronium; • Elimination is primarily through renal (70%) and biliary (20%) excretion. • Intubating dose ranges from 0.06-0.1 mg/kg
![Page 175: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/175.jpg)
REVERSAL AGENTS
Cholinesterase Inhibitors & Other Pharmacologic Antagonists to
Neuromuscular Blocking Agents
![Page 176: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/176.jpg)
AnticholinesterasesInhibit the action of acetylcholinesterase at the neuromuscular junction,
• Thus prolonging the half-life of acetylcholine and potentiating its effect, especially in the presence of residual amounts of non-depolarizing muscle relaxant at the end of surgery.
The primary clinical use of cholinesterase inhibitors, also called anticholinesterases, is to reverse nondepolarizing muscle blockade.
Some of these agents are also used to diagnose and treat myasthenia gravis.
Newer agents, such as cyclodextrins and cysteine, with superior ability to reverse neuromuscular blockade from specific agents, are being investigated
![Page 177: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/177.jpg)
Cholinergic Pharmacology
cholinergic .....effects of the neurotransmitter acetylcholine
• as opposed to the adrenergic eff ects of nor adrenaline (norepinephrine).
Synthesis & metabolism of ACh
• Acetylcholine is synthesized in the nerve terminal by the enzyme cholineacetyltransferase, which catalyzes the reaction between acetylcoenzyme A and choline• Aft er its release, acetylcholine is rapidly hydrolyzed by acetylcholinesterase (true cholinesterase) into acetate and choline.
Acetylcholine is the neurotransmitter for
• the entire parasympathetic nervous system (parasympathetic ganglions and effector cells), • parts of the sympathetic nervous system (sympathetic ganglions, adrenal medulla, and sweat glands), • some neurons in the central nervous system, and • somatic nerves innervating skeletal muscle
![Page 178: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/178.jpg)
SYNTHESIS&
METABOLISMOFAch
![Page 179: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/179.jpg)
Cholinergic receptorssubdivided...... based on their reaction to the alkaloids muscarine and nicotine
• autonomic ganglia and • skeletal muscle receptors (nicotinic receptors)
1.Nicotine stimulates the…nicotinic receptors
• bronchial smooth muscle, • salivary glands, and the • sinoatrial node (muscarinic receptors).
2. muscarine activates end-organ eff ector cells....muscarinic receptors
![Page 180: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/180.jpg)
Blockade of ACh receptors
Nicotinic receptors are blocked by muscle relaxants (also called neuromuscular blockers), and
muscarinic receptors are blocked by anticholinergic drugs....atropine.
Although nicotinic and muscarinic receptors differ in their response to some agonists (eg, nicotine, muscarine) and some antagonists (eg, vecuronium vs atropine), they both respond to acetylcholine
![Page 181: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/181.jpg)
Methacholine...primarily muscarinic agonists
• by inhalation used as a provocative test in asthma
bethanechol...primarily muscarinic agonists
• used for bladder atony,
carbachol has both muscarinic and nicotinic agonist activities.
• used topically for wide-angle glaucoma.
![Page 182: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/182.jpg)
Ach ReceptorsDistribution
&Agonists
&Antagonists
![Page 183: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/183.jpg)
![Page 184: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/184.jpg)
![Page 185: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/185.jpg)
Goals of Reversal of NM Blockade
primary goal is tomaximize nicotinic transmission with a minimum of muscarinic side effects.
![Page 186: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/186.jpg)
MECHANISM OF ACTIONNormal neuromuscular transmission critically depends on acetylcholine binding to nicotinic cholinergic receptors on the motor endplate.
• spontaneous reversal• redistribution, • metabolism, and • excretion from the body • pharmacological reversal
Nondepolarizing muscle relaxants act by competing with acetylcholine for these binding sites, thereby blocking neuromuscular transmission.
Reversal of blockade
Cholinesterase inhibitors indirectly increase the amount of acetylcholine available to compete with the nondepolarizing agent, thereby reestablishing normal neuromuscular transmission.
![Page 187: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/187.jpg)
Cholinesterase inhibitors inactivate acetylcholinesterase by reversibly binding to the enzyme
covalent bonds....neostigmine & pyridostigmine... Long duration
electrostatic attraction and hydrogen bonding....edrophonium...short duration
clinical duration of the cholinesterase inhibitors used in anesthesia......influenced by the rate of drug disappearance from the plasma.
![Page 188: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/188.jpg)
Mechanisms of action other than acetylcholinesterase inactivation
Edrophonium seems to have prejunctional effects that enhance the release of acetylcholine.
• Acetylcholine mobilization and release by the nerve may also be enhanced (a presynaptic mechanism).
Neostigmine has a direct (but weak) agonist effect on nicotinic receptors.
• paradoxically potentiate a nondepolarizing neuromuscular blockade....may cause receptor channel blockade
In excessive doses, acetylcholinesterase inhibitors
![Page 189: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/189.jpg)
Cholinesterase inhibitors prolong the depolarization blockade of succinylcholine.
Two mechanisms may explain this latter effect:
• increase in acetylcholine (which increases motor end-plate depolarization) • inhibition of pseudocholinesterase activity.
Neostigmine and to some extent pyridostigmine display some limited pseudocholinesterase-inhibiting activity, but their effect on acetylcholinesterase is much greater.
Edrophonium has little or no effect on pseudocholinesterase.
In large doses, neostigmine can cause a weak depolarizing neuromuscular blockade.
![Page 190: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/190.jpg)
Organophosphates
special class of cholinesterase inhibitors, form very stable, irreversible bonds to the enzyme Acetalcholinesterase....
• ophthalmology • pesticides.
![Page 191: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/191.jpg)
CLINICAL PHARMACOLOGY General Pharmacological
Characteristics Cholinesterase inhibitors can act at cholinergic receptors of several other organ systems
• bradycardia that • sinus arrest.
Cardiovascular receptors —Th e predominant muscarinic eff ect on the heart is
• bronchospasm (smooth muscle contraction) and • increased respiratory tract secretions.
Pulmonary receptors —Muscarinic stimulation can result in
![Page 192: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/192.jpg)
Cerebral receptors —
• Physostigmine is a cholinesterase inhibitor that crosses the bloodbrain barrier and can cause• diffuse activation of the electroencephalogram by stimulating muscarinic and nicotinic receptors within the central
nervous system. • Unlike physostigmine, cholinesterase inhibitors used to reverse neuromuscular blockers do not cross the blood–
brain barrier.
Gastrointestinal receptors —
• Muscarinic stimulation increases peristaltic activity (esophageal, gastric, and intestinal) • glandular secretions (eg, salivary). • Postoperative nausea, vomiting, • fecal incontinence
![Page 193: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/193.jpg)
Unwanted muscarinic side eff ects are minimized by
• Prior or concomitant administration of anticholinergic medications, such as • Atropine sulfate or • Glycopyrrolate.
Clearance
• Hepatic metabolism (25% to 50%) • Renal excretion (50% to 75%). • Any prolongation of action of a nondepolarizing muscle relaxant from renal or hepatic insufficiency will
probably be accompanied by a corresponding increase in the duration of action of a cholinesterase inhibitor.
![Page 194: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/194.jpg)
![Page 195: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/195.jpg)
When reversal agent should be given?
no amount of cholinesterase inhibitor can immediately reverse a block that is so intense that..... cannot be reversed if
• there is no response to tetanic peripheral nerve stimulation. • Moreover, absence of any palpable single twitches following 5 sec of tetanic stimulation at 50 Hz .
Some evidence of spontaneous recovery ...(ie, the first twitch of the train-of-four [TOF]) should be present before reversal is attempted.
The posttetanic count (the number of palpable twitches after tetanus) generally correlates with the time of return of the first twitch of the TOF and therefore the ability to reverse intense paralysis.....
![Page 196: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/196.jpg)
Example
• a palpable posttetanic twitch appears about 10 min before spontaneous recovery of the first twitch of the TOF
intermediate-acting agents, such as atracurium and vecuronium.....
• a palpable posttetanic twitch appears about 40 min before spontaneous recovery of the first twitch of the TOF
for longer-acting agents, such as pancuronium.....
![Page 197: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/197.jpg)
Factors effecting The time required to fully reverse a
nondepolarizing block 1.Choice cholinesterase inhibitor administered
2.Dose of cholinesterase inhibitor administered
3.The muscle relaxant being antagonized,
4.Extent of the blockade before reversal.
![Page 198: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/198.jpg)
![Page 199: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/199.jpg)
example
• reversal with edrophonium is usually faster than with neostigmine• large doses of neostigmine lead to faster reversal than small doses• intermediate-acting relaxants reverse sooner than long-acting relaxants• a shallow block is easier to reverse than a deep block (ie, twitch height >10%).
intermediate-acting relaxants require a lower dose of reversal agent (for the same degree of blockade) than long-acting agents, and
• concurrent excretion or metabolism provides a proportionally faster reversal of the short- and intermediate-acting agents.
![Page 200: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/200.jpg)
Factors associated with faster reversal are also associated with
• a lower incidence of residual paralysis in the recovery room and a • lower risk of postoperative respiratory complications
A reversal agent should be routinely given to all patients who have received nondepolarizing muscle relaxants unless
• full reversal can be demon-strated or • postoperative plan includes continued intubation and ventilation.
![Page 201: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/201.jpg)
Has patient reversed adequately?
A peripheral nerve stimulator should also be used to monitor the progress and confirm the adequacy of reversal.
• (100-Hz tetany > 50-Hz tetany or TOF >single-twitch height).
In general, the higher the frequency of stimulation, the greater the sensitivity of the test
• (sustained head lift >inspiratory force > vital capacity > tidal volume).
Clinical signs of adequate reversal also vary in sensitivity
• sustained tetanus for 5 sec in response to a 100-Hz stimulus in anesthetized patients or • sus-tained head or leg lift for at least 5 sec in awake patients.
Thus ....end points of recov-ery are
![Page 202: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/202.jpg)
NEOSTIGMINEPhysical Structure
• consists of a carbamate moiety......provides covalent bonding to acetylcholines-terase.
• quaternary ammonium group.....renders the molecule lipid insoluble, so that it cannot pass through the blood–brain barrier.
Dosage & Packaging• The usual dose of neostigmine ........0.04-0.08mg / kg in
combination with either • atropine 0.02 mg /kg OR 0.4 mg of atropine per 1 mg of neostigmine
or • glycopyrrolate 0.01 mg/kg OR 0.2 mg glycopyrrolate per 1 mg of
neostigmine Neostigmine takes at least 2 min to have an initial effect, and recovery from neuromuscular block is maximally enhanced by 10 min.
![Page 203: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/203.jpg)
OR0.01 mg/kg
a 0.02 mg /kg OR 0.4 mg of atropine per 1 mg of neostigmine
![Page 204: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/204.jpg)
Clinical ConsiderationsEffects of neostigmine (0.04 mg/kg) are usually apparent in 5min, peak at 10 min, and last more than 1 hr.
• 0.04 mg/kg (or 2.5 mg) if the preexisting blockade is mild to moderate
• 0.08 mg/kg (or 5 mg) if intense paralysis is being reversed
Many clinicians use a dose of
Neostigmine crosses the placenta, resulting in fetal bradycardia. .........Atropine may be a better choice of an anticholinergic agent than glycopyrrolate in pregnant
Neostigmine is also used to treat myasthenia gravis, urinary bladder atony, and paralytic ileus.
![Page 205: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/205.jpg)
OTHER CONSIDERATIONS
Recovery from neuromuscular blockade is influenced by the
• Depth of block at the time of antagonism• Clearance and half-life of the relaxant used• Other factors that aff ect neuromuscular blockade
• Drugs • Electrolyte• Acid/base balance• Temperature
![Page 206: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/206.jpg)
![Page 207: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/207.jpg)
NON-CLASSIC REVERSAL AGENTS
Two unique drugs , under investigation these agents act as selective antagonists of nondepolarizing neuromuscular blockade.
Sugammadex....Able to reverse aminosteroid-induced neuromuscular blockade
L-cysteine....Reverse the neuromuscular blocking effects of gantacurium and other fumarates.
![Page 208: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/208.jpg)
SUGAMMADEX
modified gamma-cyclodextrin ......
• SU- refers to sugar• gammadex ...... refers to the structural molecule gamma-cyclodextrin
Sugammadex is a novel selective relaxant-binding agent that is currently available for clinical use in Europe
![Page 209: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/209.jpg)
![Page 210: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/210.jpg)
![Page 211: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/211.jpg)
Physical Structure
three-dimensional structure resembles a hollow truncated cone or doughnut with a hydrophobic cavity and a hydrophilic exterior.
• Hydrophobic interactions trap the drug (eg, rocuronium) in the cyclodextrin cavity (doughnut hole), resulting in tight formation of a water-soluble guest–host complex in a 1:1 ratio.
• terminates the neuromuscular blocking action and restrains the drug in extracellular fluid where it cannot interact with nicotinic acetylcholine receptors.
• eliminated unchanged via the kidneys.
MECHANISM
![Page 212: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/212.jpg)
Clinical Considerations
doses of 4–8 mg/kg.
• injection of 8 mg/kg, given 3 min after administration of 0.6 mg/kg of rocuronium, recovery of TOF ratio to 0.9 was observed within 2 min.
produces rapid and effective reversal of both shallow and profound rocuronium-induced neuromuscular blockade
Due to hypersensitivity and allergic reactions, sugammadex has not yet been approved by the US Food and Drug Administration.
![Page 213: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/213.jpg)
L -CYSTEINEAn endogenous amino acid that is oft en added to total parenteral nutrition regimens to enhance calcium and phosphate solubility.• Ultrashort-acting neuromuscular blocker, gantacurium, and other fumarates
rapidly combine with L -cysteine in vitro to form less active degradation products (adducts).
• L -cysteine (10–50 mg/kg intravenously) given to anesthetized monkeys 1 min after these neuromuscular blocking agents.... • Abolished the block within 2–3 minReverse the neuromuscular blocking effects of gantacurium and other
fumarates.
Mechanism
Antagonism was found to be superior to that produced by anticholinesterases
Unique method of antagonism by adduct formation and inactivation is still in the investigative stage in humans.
![Page 214: Neuromuscular blocking agents & reversal in anesthesia](https://reader031.vdocument.in/reader031/viewer/2022012923/588348a01a28abbe6b8b6567/html5/thumbnails/214.jpg)
THANKS